Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Omeros Corporation stock logo
OMER
Omeros
$3.20
-3.6%
$4.45
$2.97
$13.60
$194.53M2.2711,194 shs1.70 million shs
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$23.48
-1.0%
$25.40
$11.16
$29.33
$1.10B0.52957,432 shs684,995 shs
Perrigo Company plc stock logo
PRGO
Perrigo
$26.55
-0.1%
$26.31
$23.14
$30.93
$3.65B0.461.46 million shs952,191 shs
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$31.16
-0.1%
$32.18
$25.55
$40.28
$1.75B0.71482,463 shs1.10 million shs
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Omeros Corporation stock logo
OMER
Omeros
-3.61%-0.31%+1.91%-62.22%-16.23%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-0.97%-3.10%-8.14%-5.74%-14.96%
Perrigo Company plc stock logo
PRGO
Perrigo
-0.24%+0.14%-1.90%-5.38%+3.15%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
-0.13%-3.47%-3.08%-3.50%+16.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Omeros Corporation stock logo
OMER
Omeros
3.8857 of 5 stars
3.40.00.04.43.31.70.6
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
3.2014 of 5 stars
2.22.00.03.91.52.50.6
Perrigo Company plc stock logo
PRGO
Perrigo
4.8395 of 5 stars
2.15.04.23.52.91.72.5
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.2385 of 5 stars
2.22.00.04.11.30.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$18.00462.50% Upside
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
2.33
Hold$26.4412.63% Upside
Perrigo Company plc stock logo
PRGO
Perrigo
2.25
Hold$33.0024.28% Upside
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
2.33
Hold$36.0015.53% Upside

Current Analyst Ratings Breakdown

Latest PCRX, PRGO, SUPN, and OMER Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/10/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/16/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/13/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/9/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$32.00 ➝ $30.00
5/7/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/11/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
4/8/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
4/8/2025
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$48.00 ➝ $65.00
4/1/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
4/1/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/A($3.15) per shareN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
$700.97M1.55$4.28 per share5.49$16.86 per share1.39
Perrigo Company plc stock logo
PRGO
Perrigo
$4.37B0.83$5.05 per share5.26$31.66 per share0.84
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$661.82M2.64$4.17 per share7.48$18.76 per share1.66
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Omeros Corporation stock logo
OMER
Omeros
-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
-$99.56M-$2.28N/A9.14N/A-14.78%13.78%7.00%7/29/2025 (Estimated)
Perrigo Company plc stock logo
PRGO
Perrigo
-$171.80M-$1.31N/A8.68N/A-4.16%8.93%3.87%8/1/2025 (Estimated)
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
$73.86M$1.1128.0721.64N/A9.27%12.23%9.17%8/5/2025 (Estimated)

Latest PCRX, PRGO, SUPN, and OMER Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A
5/7/2025Q1 2025
Perrigo Company plc stock logo
PRGO
Perrigo
$0.56$0.60+$0.04-$0.05$1.09 billion$1.04 billion
3/31/2025Q4 2024
Omeros Corporation stock logo
OMER
Omeros
-$0.71-$0.63+$0.08-$0.54$0.40 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
N/AN/AN/AN/AN/A
Perrigo Company plc stock logo
PRGO
Perrigo
$1.164.37%N/AN/A 23 Years
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/AN/AN/AN/AN/A

Latest PCRX, PRGO, SUPN, and OMER Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/30/2025
Perrigo Company plc stock logo
PRGO
Perrigo
quarterly$0.294.55%5/30/20255/30/20256/17/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Omeros Corporation stock logo
OMER
Omeros
N/A
1.16
1.16
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
0.48
2.41
1.99
Perrigo Company plc stock logo
PRGO
Perrigo
0.82
2.36
1.28
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A
2.44
2.26

Institutional Ownership

CompanyInstitutional Ownership
Omeros Corporation stock logo
OMER
Omeros
48.79%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
99.73%
Perrigo Company plc stock logo
PRGO
Perrigo
95.91%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
Omeros Corporation stock logo
OMER
Omeros
12.90%
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
6.40%
Perrigo Company plc stock logo
PRGO
Perrigo
0.70%
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
8.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Omeros Corporation stock logo
OMER
Omeros
21058.59 million51.04 millionOptionable
Pacira BioSciences, Inc. stock logo
PCRX
Pacira BioSciences
72046.29 million43.33 millionOptionable
Perrigo Company plc stock logo
PRGO
Perrigo
8,379137.48 million136.52 millionOptionable
Supernus Pharmaceuticals, Inc. stock logo
SUPN
Supernus Pharmaceuticals
58055.99 million51.06 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Omeros stock logo

Omeros NASDAQ:OMER

$3.20 -0.12 (-3.61%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$3.36 +0.17 (+5.16%)
As of 06/27/2025 06:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Pacira BioSciences stock logo

Pacira BioSciences NASDAQ:PCRX

$23.48 -0.23 (-0.97%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$23.48 0.00 (-0.02%)
As of 06/27/2025 06:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

Perrigo stock logo

Perrigo NYSE:PRGO

$26.55 -0.02 (-0.07%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$26.50 -0.05 (-0.18%)
As of 06/27/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Supernus Pharmaceuticals stock logo

Supernus Pharmaceuticals NASDAQ:SUPN

$31.16 -0.04 (-0.13%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$31.17 +0.01 (+0.03%)
As of 06/27/2025 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.